Navigation Links
Micromet Announces Pricing of Public Offering of Common Stock
Date:7/30/2009

clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a phase 1 clinical trial in 2009 with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option until January 2010 to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candida
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and ... candidates to participate in an investigational study of donor ... goal of this study is to determine if a ... two arthritically affected joints can help reduce pain and ... the current investigational study must be older than nine ...
(Date:8/29/2014)... A major challenge before new biotechnology ... realm of Boston-Cambridge, is gaining visibility that can lead ... the Director of Boston’s Adult Stem Cell Technology Center, ... visibility of his company an important priority since he ... to a social media marketing campaign launched ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... the food processing industry, is asking industry professionals to ... comparison of the E2 soap they’re currently using to ... Soap . Hand hygiene is critical to fighting ... processing environment. Six key criteria are identified to evaluate ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... SHANGHAI, Aug. 10 /PRNewswire-Asia-FirstCall/ ... ("China-Biotics," "the Company"), a leading Chinese firm,specializing ... of probiotics products, today announced that the ... has been,awarded the High-Technology Enterprise Certificate (the ...
... /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... Patent and Trademark Office (PTO) has issued United ... Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method ... to treat certain cancers. The patent, licensed from ...
... ... launched its revolutionary Trusted LASIK Surgeons directory service and website at ... improve their vision and find a highly qualified eye surgeon who can ... directory apart is a unique screening process ensuring that only those who ...
Cached Biology Technology:China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 2China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 2Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 3Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 4Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 5Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 6Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 7Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 8
(Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
(Date:8/28/2014)... Scientists have identified the developmental on-off switch for ... more than two-thirds of the world,s naturally derived antibiotic ... see whether it is possible to manipulate this switch ... The study, appearing August 28 in Cell , ... called cyclic-di-GMP and a larger protein called BldD ultimately ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced ... of Sports Medicine,s Conference on Integrative Physiology of ... These awards are meant to promote the ... underrepresented groups into the mainstream of the basic ... young scientists at the American College of Sports ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... superstars of urban landscapes. In addition to their intrinsic ... pollution, provide habitat for wildlife, increase property values, and ... trees decrease energy usage in urban buildings, absorb carbon ... that researchers around the world are working to find ...
... STATION, TXLandscape trees are increasingly being produced using ... practices. In contrast to field production techniques, successful ... in which trees are sequentially transferred to larger ... Problems can arise when trees are ...
... Behaviour Using Accelerometry in Cane Toads Bufo marinus ... were introduced to Australia as a control agent but now ... they enter. Predictive models that can give expansion rates as ... to maximise control efficiency but to date no study has ...
Cached Biology News:Low-tech cool: Shade trees for subtropical streets 2Planting depth affects popular landscape tree 2Cane toad accelerometry and more 2Cane toad accelerometry and more 3Cane toad accelerometry and more 4Cane toad accelerometry and more 5Cane toad accelerometry and more 6
BD BioCoat Collagen IV 150 mm Culture Dishes...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
MAb to Desmoplakin I & II Desmoplakin I & II...
... conjuction with Annexin V-FITC to distinguish cells ... apoptosis (Annexin V positive, PI negative) from ... apoptosis or already dead (Annexin V-FITC positive, ... orange range of the spectrum using a ...
Biology Products: